ACRM Conference Presentation: The injection of Ghrelin (OXE-103) improves subacute concussion symptom burden and quality of life

Written By Lindsey McClelland

A Phase 2a Concussion study of Oxeia Biopharmaceutical’s drug, OXE103, showed strong potential as an effective concussion treatment. Dr. Michael Rippee of KUMC Medical Center presented the findings during the ACRM Conference on 10/31

Lindsey McClelland
Previous

News Release: CONCUSSION DRUG STUDY SHOWS POSITIVE EARLY RESULTS
Next

Pharmaceutical Technology: A tough puzzle: complexity slows drug development for concussions